Myung‐Ju Ahn

71.9k total citations · 15 hit papers
717 papers, 32.1k citations indexed

About

Myung‐Ju Ahn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Myung‐Ju Ahn has authored 717 papers receiving a total of 32.1k indexed citations (citations by other indexed papers that have themselves been cited), including 486 papers in Pulmonary and Respiratory Medicine, 481 papers in Oncology and 139 papers in Molecular Biology. Recurrent topics in Myung‐Ju Ahn's work include Lung Cancer Treatments and Mutations (430 papers), Lung Cancer Research Studies (203 papers) and Cancer Immunotherapy and Biomarkers (125 papers). Myung‐Ju Ahn is often cited by papers focused on Lung Cancer Treatments and Mutations (430 papers), Lung Cancer Research Studies (203 papers) and Cancer Immunotherapy and Biomarkers (125 papers). Myung‐Ju Ahn collaborates with scholars based in South Korea, United States and United Kingdom. Myung‐Ju Ahn's co-authors include Keunchil Park, Jin Seok Ahn, Jong‐Mu Sun, Enriqueta Felip, Se‐Hoon Lee, Joo-Hang Kim, Ji‐Youn Han, Dong‐Wan Kim, Tony Mok and Suresh S. Ramalingam and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Myung‐Ju Ahn

692 papers receiving 31.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

2015 4.9k citations Enriqueta Felip, Ji‐Youn Han et al. profile →
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

2016 2.4k citations Tony Mok, Yi‐Long Wu et al. profile →
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 1.6k citations Pasi A. Jänne, Suresh S. Ramalingam et al. profile →
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

2019 751 citations Byoung Chul Cho, Myung‐Ju Ahn et al. profile →
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

2012 611 citations Ji‐Youn Han, Keunchil Park et al. Journal of Clinical Oncology profile →
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

2015 468 citations Benjamin Solomon, Myung‐Ju Ahn et al. Journal of Clinical Oncology profile →
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

2017 430 citations Myung‐Ju Ahn, Egbert F. Smit et al. Journal of Clinical Oncology profile →
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

2018 349 citations Yi‐Long Wu, Myung‐Ju Ahn et al. Journal of Clinical Oncology profile →
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

2019 322 citations Jin Seok Ahn, Myung‐Ju Ahn et al. profile →
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

2020 303 citations Leora Horn, Kōichi Goto et al. Annals of Oncology profile →
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 295 citations Ji‐Youn Han, Myung‐Ju Ahn et al. profile →
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

2018 225 citations Yi‐Long Wu, Jianying Zhou et al. Journal of Clinical Oncology profile →
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

2021 196 citations D.-W. Kim, Myung‐Ju Ahn et al. Annals of Oncology profile →
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

2022 95 citations Myung‐Ju Ahn, Ji‐Youn Han et al. profile →
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

2023 95 citations Tony Mok, Yi‐Long Wu et al. profile →

Peers

Countries citing papers authored by Myung‐Ju Ahn

Since Specialization

Citations

This map shows the geographic impact of Myung‐Ju Ahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myung‐Ju Ahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myung‐Ju Ahn more than expected).

Fields of papers citing papers by Myung‐Ju Ahn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Myung‐Ju Ahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myung‐Ju Ahn. The network helps show where Myung‐Ju Ahn may publish in the future.

Co-authorship network of co-authors of Myung‐Ju Ahn

This figure shows the co-authorship network connecting the top 25 collaborators of Myung‐Ju Ahn. A scholar is included among the top collaborators of Myung‐Ju Ahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Myung‐Ju Ahn. Myung‐Ju Ahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma 2024 ·Cancer Immunology Immunotherapy ·Tanguy Y. Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin J. Harrington, Maura L. Gillison, Myung‐Ju Ahn, Shunji Takahashi, Jared Weiss, Jean‐Pascal Machiels, Shrujal S. Baxi, Valerie L. Baker, Brent Evans, Nassim Morsli, Jill Walker, (unknown), Anne L’Hernault, Amanda Psyrri	6
2	P.087 Factors affecting health-related quality of life among adult meningioma patients: a systematic review 2024 ·Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·Kim Jonas, (unknown), Myung‐Ju Ahn, Michael D. Cusimano	0
3	Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18 2024 ·JTO Clinical and Research Reports ·(unknown), (unknown), Young Saing Kim, Keon Uk Park, Jang Ho Cho, Hong-Sik Kim, Ki Hyeong Lee, (unknown), Il Hwan Kim, Kyung Hee Lee, Gyeong‐Won Lee, Seong Yoon Yi, Byeong‐Cheol Ahn, Min-Young Lee, Hyun Ae Jung, Sehhoon Park, Jong‐Mu Sun, Jin Seok Ahn, Se‐Hoon Lee, Myung‐Ju Ahn	1
4	PP01.72 Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304) 2024 ·Journal of Thoracic Oncology ·Luis Paz-Ares Rodríguez, Enriqueta Felip, Myung‐Ju Ahn, Fiona Blackhall, Hossein Borghaei, Byoung Chul Cho, Melissa L. Johnson, Suresh S. Ramalingam, Martin Reck, Tony T. Jiang, Chia‐Hsin Ju, Mukul Minocha, Sujoy Mukherjee, Gaurav Suri, Gonzálo Recondo, Pablo Martínez	1
5	PP01.82 Tumor-Naïve Pre-Surgical ctDNA Detection is Prognostic in Stage I Lung Adenocarcinoma (LUAD), Associating with PD-L1 Positivity and High-Grade Histological Subtype 2024 ·Journal of Thoracic Oncology ·Tae Hee Hong, Soohyun Hwang, Chris Abbosh, Abhijit Dasgupta, Violeta Beleva Guthrie, Tiffany Hung, Joerg Bredno, Jill Walker, Xiaojin Shi, Tsveta Milenkova, Leora Horn, Joon Young Choi, Ho Yun Lee, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Darren Hodgson, Hong Kwan Kim, Myung‐Ju Ahn	0
6	A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2023 ·Targeted Oncology ·Albiruni Ryan Abdul Razak, Hung‐Ming Wang, Jang‐Yang Chang, Myung‐Ju Ahn, Pamela N. Münster, George R. Blumenschein, Benjamin Solomon, Wan‐Teck Lim, Ruey‐Long Hong, David G. Pfister, Nabil F. Saba, Se‐Hoon Lee, Carla van Herpen, Cornelia Quadt, Douglas Bootle, Lars Blumenstein, David Demanse, Jean‐Pierre Delord	10
7	Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant ( EGFR m ⁺ ) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 2023 ·Journal of Clinical Oncology ·Yi‐Long Wu, Qing Zhou, Jie Wang, Yan Yu, Ligang Xing, (unknown), Ying Cheng, (unknown), Yun Fan, Jianhua Shi, Guojun Zhang, Jiuwei Cui, Jianying Zhou, Yong Song, Wu Zhuang, Zhiyong Ma, Yanping Hu, Gaofeng Li, Xiaorong Dong, Myung‐Ju Ahn	8
8	A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial 2023 ·Cancer Research and Treatment ·(unknown), Sun Min Lim, Hee Kyung Ahn, Yun‐Gyoo Lee, Keun-Wook Lee, Myung‐Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim	4
9	Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2023 ·Cancer Research and Treatment ·Hana Kim, Sehhoon Park, Hyun Ae Jung, Se‐Hoon Lee, Keunchil Park, Yong Chan Ahn, Dongryul Oh, Myung‐Ju Ahn	14
10	MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02 2023 ·Journal of Thoracic Oncology ·Pasi A. Jänne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, (unknown), (unknown), Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, (unknown), Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, D.-W. Kim, (unknown), Fang Cheng, Ayumi Taguchi, Yun Cheng, Kōichi Goto	2
11	Artificial intelligence‐powered spatial analysis of tumor‐infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma 2023 ·Head & Neck ·(unknown), Yoojoo Lim, Chan‐Young Ock, Gahee Park, Seonwook Park, (unknown), Minuk Ma, (unknown), Eun Joo Kang, Myung‐Ju Ahn, Keun‐Wook Lee, Jung Hye Kwon, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, (unknown), Bhumsuk Keam	5
12	Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma 2021 ·Clinical Cancer Research ·Eun Joo Kang, Myung‐Ju Ahn, Chan-Young Ock, Keun‐Wook Lee, Jung Hye Kwon, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Byung‐Ho Nam, Sung‐Bae Kim, Bhumsuk Keam	39
13	Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or Without Pembrolizumab in Patients with Inoperable Stage I/IIA Non–Small-Cell Lung Cancer (NSCLC): KEYNOTE-867 2020 ·International Journal of Radiation OncologyBiologyPhysics ·Salma K. Jabbour, Baerin Houghton, Andrew Robinson, Xavier Quantin, Thomas Wehler, Dariusz M. Kowalski, Myung‐Ju Ahn, Mustafa Erman, Giuseppe Giaccone, Hossein Borghaei, (unknown), J. Zhang, Francis Ribeiro de Souza, Roy H. Decker	0
14	A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy 2020 ·Annals of Oncology ·Seo‐Young Park, (unknown), (unknown), S.T. Kim, Jin Hyoung Kang, Byoung Chul Cho, K.H. Lee, (unknown), Jong‐Mu Sun, S.-H. Lee, Jin Seok Ahn, K. Park, Myung‐Ju Ahn	122
15	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors 2019 ·Clinical Cancer Research ·Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su‐Hyung Park, Keunchil Park, Myung‐Ju Ahn, Eui‐Cheol Shin	132
16	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC 2019 ·Journal of Thoracic Oncology ·Sehhoon Park, Hayoon Lee, Boram Lee, Se‐Hoon Lee, Jong‐Mu Sun, Woong‐Yang Park, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park	58
17	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3) breakdown → 2018 ·Journal of Clinical Oncology ·Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Ji‐Youn Han, Nobuyuki Katakami, Hye Ryun Kim, Rachel Hodge, Paramjit Kaur, Andy Brown, Dana Ghiorghiu, Vassiliki A. Papadimitrakopoulou, Tony Mok	349
18	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib 2015 ·Clinical Cancer Research ·Ji Yun Lee, Jong‐Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa‐Na Song, Bo Mi Ku, Jiae Koh, (unknown), Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	28
19	The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor 2012 ·Molecular Cancer Therapeutics ·Young-Wook Kim, Jeong‐Hun Ko, (unknown), Amir Abolhoda, Jin Seok Ahn, (unknown), Myung‐Ju Ahn, Keunchil Park	144
20	Intraventricular or epidural injection of morphine for severe pain 1989 ·min - Minimally Invasive Neurosurgery ·Chul Young Choi, (unknown), Myung‐Ju Ahn, (unknown), (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact